Vanta Bioscience Ltd Directors Report.

Dear Members,

Your Directors have pleasure in presenting herewith the 2ndAnnual Report on the business of the Company together with the Financial Statements for the financial year ended March 31, 2018.

ABOUT THE COMPANY

Vanta Bioscience is an emerging, full service preclinical contract research organization, operating out of Chennai, India. Vanta Bioscience is established as a center of excellence for GLP toxicology and safety assessment.

FINANCIAL HIGHLIGHTS

The following are the financial highlights of the Company:

(Amount in Rs.)
PARTICULARS 31.03.2018
Total Revenue 4,03,87,179
Total Expenses 3,72,37,602
Profit before Tax 31,49,577
Current Tax 6,00,152
Deferred Tax 22,76,497
Profit after Tax 2,72,928

*There were no operations during the financial year 2016-17

LISTING ON SME PLATFORM OF BSE

Pursuant to the initial public offering, the equity shares of the Company were listed on the SME Platform of BSE Ltd. w.e.f October 06, 2017 vide BSE Notice 20171005-33 dated October 05, 2017.

DIVIDEND

This being the first year of commercial operations, the Board has not recommended any dividend for the financial year 2017-18.

TRANSFER TO RESERVES

No amount has been transferred to general reserves during the year under review. Reserves and Surplus are disclosed in Note 3 of the financial statements.

DEPOSITS

The Company has neither accepted nor renewed any deposits from public as defined under the provisions of Companies Act, 2013 and Companies (Acceptance of Deposits) Rules, 2014.

DETAILS OF DIRECTORS AND KEY MANAGERIAL PERSONNELS

In accordance with the provisions of Section 152 of the Companies Act, 2013, Dr. Vyasmurti Madhavrao Shingatgeri (DIN: 07728757), Whole Time Director of the Company is liable to retire by rotation, being eligible offers himself for re-appointment.

During the year under review, the following changes took place on the Board of the Company:

S. No Name of the Director Type of Change W.e.f
1 Dr. Vyasmurti Madhavrao Shingatgeri (DIN 07728757) Regularized as Director and appointment as Whole Time Director for a period of 3 years April 01, 2017 (EGM)
2 Mr. Dopesh Raja Mulakala (DIN 01176660) Change in Designation Appointed as Managing Director for a period of 3 years April 18, 2017
3 Dr. Gonuguntla Kathyayani (DIN 07824881) Appointment as Additional Director Independent Category for 5 years May 19, 2017
4 Dr. Padmanabhuni Venkata Appaji (DIN 02614167) Regularized as Director May 31, 2017 (AGM)
5 Dr. Jang Bahadur Gupta (DIN 07751205) Regularized as Director May 31, 2017 (AGM)
6 Dr. Gonuguntla Kathyayani (DIN 07824881) Regularized as Director May 31, 2017 (AGM)
7 Mr. Sadhanala Venkata Rao (DIN 02906370) Appointment as Additional Director & CEO for a period of 3 years January 05, 2018
8 Mr. Sadhanala Venkata Rao (DIN 02906370) Regularized as Director and Appointment as CEO & Whole Time Director February 07, 2018(EGM)

The following are the details of appointment and resignation of KMPs during the year:

S. No Name Type of Change W.e.f
1 Mr. Zoheb Sultan Ali Sayani Appointed as Company Secretary & Compliance officer May 02, 2017
2 Mr. Sadhanala Venkata Rao Appointment as Chief Financial Officer May 02, 2017
3 Mr. Sadhanala Venkata Rao Resignation as Chief Financial Officer January 05, 2018
4 Mr. Sadhanala Venkata Rao Appointment as CEO January 05, 2018
5 Mr. A Kiran Kumar Appointment of CFO July 04, 2018

The Company has received declarations from all the Independent Directors of the Company confirming that they meet the criteria of independence as prescribed under the Companies Act, 2013.

BOARD EVALUATION

The Board evaluated the effectiveness of its functioning and that of the Committees and of individual directors by seeking their inputs on various aspects of Board/Committee Governance.

The aspects covered in the evaluation included the contribution to and monitoring of corporate governance practices, participation in the long-term strategic planning and the fulfilment of Directors obligations and fiduciary responsibilities, including but not limited to, active participation at the Board and Committee meetings. The Chairman of the Board had one-on-one meetings with the Independent Directors. These meetings were intended to obtain Directors inputs on effectiveness of Board/Committee processes. Further, the Independent Directors at their meeting, reviewed the performance of Board, Chairman of the Board and of Non-Executive Directors.

STATUTORY AUDITORS

M/s. KBS & Associates, Chartered Accountants were the first auditors of the Company and have carried out the statutory audit for the FY 2016-17. They were further appointed as the statutory auditors for a period of 5 years in the 1st annual general meeting of the Company held on May 31, 2017.

During the year under review, M/s. KBS & Associates, Chartered Accountants have submitted their resignation letter dated November 09, 2017. The Board in its meeting held on November 09, 2017 noted their resignation and appointed M/s. Mathesh & Ramana, Chartered Accountants as the statutory auditors of the Company to carry out the statutory audit for FY 2017-18. The said appointment was in lieu of the casual vacancy caused and was subject to ratification by shareholders in their meeting.

The shareholders in their extra ordinary general meeting held on February 07, 2018 have ratified their appointment as statutory auditors for FY 2017-18 and the said appointment is valid till the ensuing annual general meeting The Audit Committee and the Board have recommended the appointment of M/s. Mathesh & Ramana, Chartered Accountants (FRN 002020S) as the statutory auditors of the Company for a period of 5 years. The said appointment is subject to the approval of the shareholders in the ensuing annual general meeting. The said resolution is Item No. 3 of the Notice which forms part of this annual report.

In this regard, the Company has received a certificate from the auditor to the effect that if they are appointed, it would be in accordance with the provisions of Section 141 of the Companies Act, 2013.

AUDITORS REPORT

The Auditors Report does not contain any qualification. Notes to Accounts and Auditors remarks in their report are self-explanatory and do not call for any further comments.

SECRETARIAL AUDIT REPORT

Mr. Tapasvilal Deora of M/s. Tapasvilal Deora & Associates, Practicing Company Secretary were appointed to conduct the secretarial audit of the Company for the financial year 2017-18, as required under Section 204 of the Companies Act, 2013 and rules there-under. The secretarial audit report for FY 2017-18 forms part of this Annual Report as Annexure – I.

The Report does not contain any qualification and is self-explanatory and do not call for any further comments.

CHANGES IN THE AUTHORIZED AND PAID UP CAPITAL

During the year under review, the authorized share capital of the Company was increased from Rs. 4.50 Cr to Rs. 7.50 Cr in the extra ordinary general meeting of members held on April 29, 2017.

The following are the details of changes in the paid up capital during the year under review

S. No. Type of Allotment No. of equity shares Allotment Date
1 Rights Issue 3,34,000 April 28, 2017
2 Rights Issue 2,36,000 May 30, 2017
3 Initial Public Offering 15,12,000 October 05, 2017
Total 20,82,000

The paid up capital of the Company as at the end of the financial year was Rs.5,72,80,000/- (Rupees Five Crore Seventy Two Lakhs and Eighty Thousand Only) comprising of 57,28,000 (Fifty Seven Lakh and Twenty Eight Thousand) equity shares of Rs. 10/- (Rupees Ten Only) each.

AUDIT COMMITTEE

The Audit Committee was constituted pursuant to a resolution of the Board dated May 9, 2017. The Audit Committee comprises:

Name of Director Status in Committee Nature of Directorship
Dr. Padmanabhuni Venkata Appaji Chairman Independent Director
Dr. Jang Bahadur Gupta Member Independent Director
Mr. Dopesh Raja Mulakala Member Managing Director
8

STAKEHOLDERS RELATIONSHIP COMMITTEE

The Stakeholders Relationship Committee was constituted by a resolution of our Board dated May 9, 2017.The Stakeholders Relationship Committee comprises:

Name of Director Status in Committee Nature of Directorship
Dr. Padmanabhuni Venkata Appaji Chairman Independent Director
Dr. Jang Bahadur Gupta Member Independent Director
Mr. Dopesh Raja Mulakala Member Managing Director

NOMINATION AND REMUNERATION POLICY

A committee of the Board has been formed which is named as "Nomination and Remuneration Committee" which has been entrusted with the task to recommend a policy of the Company on Directors appointment and remuneration, including criteria for determining qualifications, positive attributes, independence of a Director and other matters and to frame proper systems for identification, appointment of Directors & KMPs, Payment of Remuneration to them and evaluation of their performance and to recommend the same to the Board from time to time. Nomination and Remuneration Policy of the Company is enclosed herewith as Annexure – II. The Nomination and Remuneration Committee include the following:

Name of Director Status in Committee Nature of Directorship
Dr. Jang Bahadur Gupta Chairman Independent Director
Dr. Padmanabhuni Venkata Appaji Member Independent Director
Dr. Kathyayani Gonuguntla Member Independent Director

CORPORATE SOCIAL RESPONSIBILITY

The provisions of Section 135 of the Companies Act, 2013 in connection with corporate social responsibility are not applicable to the Company.

VIGIL MECHANISM

A vigil mechanism for directors and employees to report genuine concerns has been established. The Vigil Mechanism Policy has been uploaded on the website of the Company.

RISK MANAGEMENT POLICY

The Risk Management is overseen by the Audit Committee of the Company on a continuous basis. The Committee oversees Companys process and policies for determining risk tolerance and review managements measurement and comparison of overall risk tolerance to established levels. There are no material risks which threaten the very existence of the company.

INTERNAL FINANCIAL CONTROLS

The Company has adequate internal financial controls which commensurate with the size of the business of the Company.

The Board has appointed M/s. K B S & Associates., Chartered Accountants (FRN 011208S) as the Internal Auditors of the Company for conducting the Internal Audit of the Company for a period of 3 financial years i.e. from the financial year 2017 - 2018 till the financial year 2019-2020

DIRECTORS RESPONSIBILITY STATEMENT

Pursuant to Section 134 (5) of the Companies Act, 2013 Your Directors confirm that: i. in preparation of annual accounts for the financial year ended March 31, 2018 the applicable accounting standards have been followed along with proper explanation relating to material departures; ii. the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give true and fair view of the state of affairs of the Company at the end of the financial year ended March 31, 2018 and of the profit and loss of the Company for the year;

iii. the Directors have taken proper and sufficient care for their maintenance of adequate accounting records in accordance with the provisions of the Companies Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

iv. the Directors had prepared the annual accounts on a going concern basis;.

v. the Directors, had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively.

vi. the Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE OUTGO

Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014, is enclosed herewith as Annexure-III.

EXTRACT OF ANNUAL RETURN

The details forming part of the extract of the Annual Return in Form MGT-9 is annexed herewith as Annexure –IV.

BOARD AND COMMITTEE MEETINGS

The Board and committee meetings of the Company were held in compliance with all the applicable provisions of the Companies Act, 2013, SEBI (LODR) Regulations, 2015 and the secretarial standards.

PARTICULARS OF EMPLOYEES

Pursuant to Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, during the financial year no employee was in receipt of remuneration of Rs. 1.02 Crore or more, or where employed for part of the year was in receipt of Rs. 8.5 Lakh or more a month.

Disclosure under Rule 5 of the Companies(Appointment & Remuneration of Managerial Personnel) Rules, 2014 is enclosed as Annexure – V.

MANAGEMENT DISCUSSION AND ANALYSIS

Management Discussion and Analysis Report is enclosed as Annexure - VI to this report.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

During the year under review, the Company has not granted any Loans or given guarantees under Section 186 of the Companies Act, 2013.

The Company has made investments in mutual funds and details of the same are disclosed in Note 43 of the financial statements.

RELATED PARTY TRANSACTIONS

There were no materially significant related party transactions with the Companys Promoters, Directors, Management or their relatives, which could have had a potential conflict with the interests of the Company. All related party transactions entered by the Company under Section 188 of the Companies Act, 2013 are at arms length. These related party transactions have been entered considering the business requirements, administrative convenience and in the best interest of the Company.

Details of material related party transactions under Section 188 of the Companies Act, 2013 are disclosed in AOC-1 enclosed as Annexure VII. The related party transactions have been approved/ratified by the shareholders in the extra ordinary general meeting held on February 07, 2018. Details of all related party transactions are disclosed in Note 31 of the financial statements.

DETAILS OF SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES

The Company does not have any associate, joint venture or subsidiaries as on March 31, 2018.

There are no companies which have become or ceased to be its Subsidiaries, joint ventures or associate companies during the financial year 2017-2018.

GENERAL

Your Directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review:

1. Issue of equity shares with differential rights as to dividend, voting or otherwise.

2. Issue of shares (including sweat equity shares) to employees of the Company under any scheme.

3. No significant or material orders were passed by the Regulators or Courts or Tribunals which impact the going concern status and Companys operations in future.

4. No material changes and commitments affecting the financial position of the Company have occurred between the end of the financial year and date of report.

5. No change in the nature of business of the Company.

The Company has complied with all the provisions of the secretarial standards as applicable to the Company. The Company being listed on SME Exchange, Para C, D and E of Schedule-V of SEBI (LODR) Regulations, 2015 in connection with disclosures in the annual report are not applicable to the Company.

Your Directors further state that during the year under review, there were no cases filed/registered pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

ACKNOWLEDGEMENT

Your Directors place on record their appreciation of the continued patronage extended to the Company by bankers, dealers, customers, suppliers, employees and shareholders. The trust reposed in your Company by its esteemed customers helped stabilized growth during the year review.

Your Company also acknowledges the support and guidance received from its Bankers, other government agencies during the year under review and look forward to continuing support.

For and on behalf of the Board
Sd/- Sd/-
Dopesh RajaMulakala Sadhanala Venkata Rao
Managing Director CEO & Whole Time Director
DIN: 01176660 DIN: 02906370
July 20, 2018
Secunderabad.

Annexure – II

Remuneration Policy for Directors, Keymanagerial Personnel and Other Employees

1. INTRODUCTION:

1.1 VANTA BIOSCIENCE LIMITED ("VBS") recognizes the importance ofaligning the business objectives with specific and measureable individual objectives and targets. The Company has therefore formulated the remuneration policy for its directors, key managerial personnel and other employees keeping in view the following objectives: 1.1.1 Ensuring that the level and composition of remuneration is reasonable and sufficient to attract, retainand motivate, to run the company successfully.

1.1.2 Ensuring that relationship of remuneration to performance is clear and meets the performance bench marks.

1.1.3 Ensuring that remuneration involves a balance between fixed and incentives pay reflecting short andlong term performance objectives appropriate to the working of the company and its goals.

2. SCOPE AND EXCLUSION:

2.1This Policy sets out the guiding principles for the Nomination and Remuneration Committee for recommending to the Board the remuneration of thedirectors, key managerial personnel and other employees of the Company.

3. TERMS AND REFERENCES:

In this Policy, the following terms shall have the following meanings: 3.1"Director" means a director appointed to the Board of a Company. 3.2"Key Managerial Personnel" means i. the Chief Executive Officer or the managing director or the manager; ii. the company secretary; iii. the whole-time director; iv. the Chief Financial Officer; and v. such other officer as may be prescribed under the Companies Act, 2013

3.3"Nomination and Remuneration Committee" means the committee constituted by VBSs Board in accordance with the applicable provisions of the Companies Act, 2013 and the Listing Regulations.

4. POLICY:

4.1 Remuneration to Executive Directors and Key Managerial Personnel

4.1.1 The Board, on the recommendation of the Nomination and Remuneration (NAR) Committee, shall review and approve the remuneration payable to the Executive Directors of the Company within the overall limits approved by the shareholders.

4.1.2 The Board, on the recommendation of the Committee, shall also review and approve theremuneration payable to the Key Managerial Personnel of the Company.

4.1.3 The Annual Plan and Objectives for Executive Directors and Senior Executives (ManagementCommittee) shall be reviewed by the Committee as the case may be and Annual Performance Bonus will be approved by the Committee based on the achievements against the Annual Plan and Objectives as may be decided by the Committee.

4.2 Remuneration to Non-Executive Directors

4.2.1 The Board, on the recommendation of the Committee, shall review and approve the remunerationpayable to the Non-Executive Directors of the Company within the overall limits approved by theshareholders and in accordance with the provisions of the Companies Act and Listing Regulations.

4.2.2 Non-Executive Directors shall be entitled to sitting fees for attending the meetings of the Board and the Committees thereof.

4.3 Remuneration to other employees

4.3.1 Employees shall be assigned grades according to their qualifications and work experience,competencies as well as their roles and responsibilities in the organization. Individual remuneration shallbe determined within the appropriate grade and shall be based on various factors such as job profile, skillsets, seniority, experience and prevailing remuneration levels for equivalent jobs.

5. Secretary

The Company Secretary of the Company shall act as Secretary of the NR Committee.

Annexure – III

STATEMENT PURSUANT TO SECTION 134(3)(M) OF THE COMPANIES ACT, 2013 READ WITH RULE 8 OF

THE COMPANIES (ACCOUNTS) RULES, 2014 (A) Conservation of energy-(i) the steps taken or impact on conservation of energy:Nil (ii) the steps taken by the company for utilizing alternate sources of energy:Nil (iii) the capital investment on energy conservation equipments: Nil

(B) Technology absorption-

(i) the efforts made towards technology absorption:Nil

(ii) the benefits derived like product improvement, cost reduction, product development or import substitution:Nil (iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)-

(a) thedetails of technology imported: Nil
(b) the year of import: Nil
(c) whether the technology been fully absorbed: Nil
(d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof: Nil

(iv)the expenditure incurred on Research and Development:Rs. 4,86,22,591/-

(C) Foreign exchange earnings and Outgo-

The Foreign Exchange earned in terms of actual inflows during the year : Rs 43,59,941/-The Foreign Exchange outgo during the year in terms of actual outflows:

S. No. Particulars Amount (Rs.)
1 Value of Imports 1,11,36,800
2 Expenditure in foreign currency 5,92,200
Total 1,17,29,000

Note : During the year, there was a Foreign Exchange Loss of Rs. 6,611 to the Company.

For and on behalf of the Board
Sd/- Sd/-
Dopesh RajaMulakala Sadhanala Venkata Rao
Managing Director CEO & Whole Time Director
DIN: 01176660 DIN: 02906370
July 20, 2018
Secunderabad

Annexure V

Disclosures under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

i. The ratio of the remuneration of each director to the median remuneration of the employees of the company -

S.No. Name of Director Remuneration Median Employee Ratio
Salary
1 Mr. Mulakala Dopesh Raja 2,727,956 262,104 10.4:1
2 Mr. Mulakala Mohan Krishna NIL NIL NIL
3 Dr. Padmanabhuni Venkata Appaji NIL NIL NIL
4 Mr. Sadhanala Venkata Rao 1,800,000 262,104 6.9:1
5 Dr. Vyasmurti Madhavrao Shingatgeri 5,975,952 262,104 22.8:1
6 Dr. Jang Bahadur Gupta NIL NIL NIL
7 Dr. Gonuguntla Kathyayani NIL NIL NIL

ii. The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive officer, Company Secretary or manager, if any, in the Financial Year: The shareholders of the Company in their extra ordinary general meetings have approved the remuneration being paid to Mr. Mulakala Dopesh Raja, Managing Director, Dr. Vyasmurti Madhavrao Shingatgeri, Whole Time Director and Mr. Sadhanala Venkata Rao, CEO and Whole Time Director. Mr. Sadhanala Venkata Rao resigned as CFO of the Company was appointed as CEO and Whole Time Director of the Company.

Details of appointments, change in designation & remuneration of all the Directors are mentioned in the Boards Report and MGT-9.

There was no remuneration paid to any director during the previous year. iii. The percentage increase in the median remuneration of the employees in the financial year: Nil iv. There were 48 Permanent employees on the rolls of the Company, as on March 31, 2018. v. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration; The shareholders of the Company in their extra ordinary general meetings have approved the remuneration being paid to Mr. Mulakala Dopesh Raja, Managing Director, Dr. Vyasmurti Madhavrao Shingatgeri, Whole Time Director and Mr. Sadhanala Venkata Rao, CEO and Whole Time Director.

Mr. Sadhanala Venkata Rao resigned as CFO of the Company was appointed as CEO and Whole Time Director of the Company.

Details of appointments, change in designation & remuneration of all the Directors are mentioned in the Boards Report and MGT-9.

There was no remuneration paid to any director during the previous year. FY 2016-17 being the first financial year, there were no operations and also no employees in the Company. vi. The key parameters of any variable component of remuneration availed by the directors; 20% of total salary is variable component which will be paid after successful completion of the KRAs fixed by the company for Mr. Sadhanala Venkata Rao, CEO & WTD. vii. Affirmation that the remuneration is as per the remuneration policy of the Company.

The remuneration paid to Directors is as per the remuneration policy of the Company.

viii. Top 10 Employees in terms of remuneration:

Name Age Qualification Designation Date of commencement employment Experience Gross (years) Nature of employment Remmune ration Per Month No of equity shares Previous Employment Relative Direc tor if any of
VYAS MADHAVRAO SHINGATGERI 56 PHD (Veterinary- Animal Director 01-04-2017 17 Permanent 4,97,996 50,000 Sun Pharma No
DOPESH RAJA MULAKALA 32 Biotechnology MBA, PGDMA Managing Director 01-04-2017 10 Permanent 2,47,996 1,94,000 Sarvotham Care Limited Yes
VENKAT RAO SADHANALA 49 CA,CS,LLB CEO/Director 01-04-2017 28 Permanent 2,00,000 N ICOM Ltd No
DEEPAK SHARMA 50 MVSc (Veterinary- Animal Biotechnology Dy. TFM 01-04-2017 21 Permanent 2,06,330 N Sun Pharma No
DR.JAIPRAKASH JAYSINGRAO B 42 MVSC Ph.D Assistant Director 01-04-2017 16 Permanent 1,47,996 N Sun Pharma No
SATHYA TN 36 (Biotechnology- Toxicology), DABT (Toxicology Principle Scientist 01-04-2017 12 Permanent 7,85,959 N IIBAT No
DR.THRIPURASUNDARI 32 MSC PHD Sr. Scientist 01-04-2017 12 Permanent 65,079 N IIBAT No
NAMRATA SINGH 36 Msc Microbiology Sr. Manager(BDM) 15-05-2017 12 Permanent 68,829 N Bio Needs India Private Ltd No
DVS MURALI 50 MBA (Finance) Manager 24-04-2017 27 Permanent 62,500 N Lanco Infratech Limited No
K VISWANATHAN 33 MSC Senior Research Scientist 01-04-2017 12 Permanent 60,496 N ROTAM No

Annexure VII

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the

Companies (Accounts) Rules, 2014

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arms-length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arms length basis: NIL

2. Details of contracts or arrangements or transactions at Arms length basis: The details of material contracts or arrangements or transactions at arms length basis are as:

Name of the related party Nature of Relationship Nature of contract Duration of Contracts Salient Terms Amount (In Rs.) Date of Board Meeting
Sarvotham Solution Limited Company in which Director is a Director (Mohan Krishna Mulakala and Dopesh Raja Mulakala) Consulting Services for technical due diligence -NA- Consulting Services for technical due diligence 30,72,720 01.04.2017
M. Sujana Sheela Relative of Director (Mohan Krishna Mulakala) & Promoter Group Rent 3 years Rent paid for property being used as registered office. Lease Period - 3 years Other terms and conditions as mentioned in the rental agreement 54,000 01.04.2017

 

For and on behalf of the Board
Sd/- Sd/-
Dopesh RajaMulakala Sadhanala Venkata Rao
Managing Director CEO & Whole Time Director
DIN: 01176660 DIN: 02906370